reviewed april 2026|next review october 2026|88 physicians psi has verified|103 published studies
Pemvidutide
Pemvidutide is a dual GLP-1/glucagon receptor agonist developed by Altimmune that demonstrated approximately 10-15% body weight loss and significant liver fat reduction in Phase II, with primary development focused on MASH.
Evidence landscape: 103 published studies
103 published items. 19 human studies and 78 animal studies.
- 19 Human
- 78 Animal
- 6 Reviews
Not FDA-approved. Phase II trials completed. Primary development focus is on MASH (metabolic dysfunction-associated steatohepatitis). No regulatory submission has been filed.
Available only through clinical trial enrollment. Not available through pharmacies or specialty pharmacies.
Dual GLP-1/glucagon receptor agonist, same mechanism class as survodutide and mazdutide. Development strategy emphasizes the hepatic benefits of the glucagon component rather than competing directly on weight loss.
PSI Assessment
A dual GLP-1/glucagon receptor agonist that demonstrated approximately 10-15% body weight loss and significant liver fat reduction in Phase II trials, pemvidutide is being developed by Altimmune with a particular focus on MASH (metabolic dysfunction-associated steatohepatitis). The liver fat reduction signal is the primary differentiator in the development strategy: while several dual agonists target weight loss, pemvidutide's clinical program emphasizes the hepatic benefits of the glucagon component.
Approximately 10-15% weight loss in Phase II. Development focused on liver fat reduction and MASH. The hepatic signal is the strategic differentiator.
The mechanism is dual GLP-1/glucagon receptor agonism with emphasis on hepatic effects. The glucagon arm drives hepatic lipid oxidation, reducing liver fat content. The GLP-1 arm provides appetite suppression and glycemic improvement. Altimmune's development strategy prioritizes the MASH indication, where liver fat reduction is the primary clinical endpoint, rather than competing directly on body weight loss against larger programs.
What the evidence supports
Phase II data demonstrates 10-15% body weight loss and significant liver fat reduction. The dual GCG/GLP-1 mechanism adds hepatic fat oxidation beyond GLP-1 alone. The MASH-focused development strategy targets a specific unmet clinical need where glucagon receptor activation has a mechanistic advantage.
What is not yet established
Phase III efficacy for MASH (primary development focus). Whether pemvidutide's liver fat reduction translates to improvement in liver fibrosis and clinical outcomes. How pemvidutide compares to survodutide or semaglutide for MASH. Regulatory pathway and timeline.
Research Evidence
The findings below cover what Phase II data has established for both weight loss and liver fat reduction, and where the MASH development focus currently stands.
Evidence by condition
Evidence dimensions across pemvidutide's investigated applications. MASH and obesity have Phase II human data. Metabolic syndrome evidence is primarily from animal studies.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| MASH/Liver Disease | ||||
| Obesity | ||||
| Metabolic Syndrome |
Phase IIa MOMENTUM trial demonstrated significant weight loss (approximately 10-15%) and liver fat reduction. The liver fat signal is the primary development focus.
Phase II data is encouraging but the MASH drug development field has a high rate of late-stage trial failures.
The glucagon component specifically targets hepatic fat oxidation, a mechanism distinct from GLP-1-only approaches and potentially advantageous for MASH.
Whether liver fat reduction translates to improvement in liver fibrosis and long-term clinical outcomes is not established.
Altimmune's development strategy prioritizes MASH over weight loss, differentiating pemvidutide from survodutide and other dual agonists competing primarily on body weight endpoints.
The MASH-focused strategy targets a specific unmet clinical need but also means a narrower initial market compared to obesity-focused programs.
19 Human|78 Animal|6 Reviews
View all 103 indexed studiesHow Pemvidutide Works
Pemvidutide is a dual GLP-1/glucagon receptor agonist (ALT-801) developed by Altimmune, with primary development focused on MASH.
Pemvidutide activates GLP-1 (reduces appetite) and glucagon (increases energy burning and reduces liver fat). The glucagon arm drives the liver to burn stored fat directly, making this compound particularly relevant for fatty liver disease.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Pemvidutide activates GLP-1 receptors for appetite suppression and glycemic control, and glucagon receptors for enhanced hepatic fat oxidation, energy expenditure, and amino acid catabolism. The glucagon component specifically targets liver fat accumulation.
What is Pemvidutide being studied for?
Researchers are studying Pemvidutide across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Pemvidutide overall. This means a compound can have human studies for one condition but only animal data for another.
MASH/Liver Disease
·Human TrialsPhase II data showed significant liver fat reduction. The glucagon component specifically targets hepatic fat oxidation, making pemvidutide particularly relevant for MASH.
Limitations: Whether liver fat reduction translates to improvement in liver fibrosis and clinical outcomes is not established. The MASH drug development field has a high rate of late-stage failures.
Obesity
·Human TrialsPhase II data showed approximately 10-15% body weight loss. Weight loss is a secondary endpoint to the MASH development focus.
Limitations: Not competing directly on weight loss against larger programs (survodutide, tirzepatide). Obesity is not the primary development indication.
Metabolic Syndrome
·Animal StudiesThe dual mechanism addresses multiple metabolic parameters including body weight, liver fat, and glycemic control.
Limitations: Metabolic syndrome is not a development target. Dedicated trials have not been conducted.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Phase II trials completed. No regulatory submission has been filed.
Availability: Available only through clinical trial enrollment. Not available through any pharmacy channel.
Class context: Safety profile consistent with incretin-based therapies. GI side effects are the most commonly reported adverse events.
Safety profile is consistent with incretin-based therapies. GI side effects (nausea, diarrhea) are the most commonly reported adverse events. Pemvidutide is investigational and not FDA-approved.
Questions and Comparisons
Questions the evidence raises for a Pemvidutide discussion.
Comparison and Related Research
Pemvidutide is most often compared with other dual agonists targeting MASH and obesity.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Randomized, double-blind, placebo-controlled trial evaluating pemvidutide (ALT-801) in adults with metabolic dysfunction-associated steatotic liver disease (MASLD). Treatment produced significant reductions in liver fat content measured by MRI-proton density fat fraction, along with improvements in liver enzymes and metabolic biomarkers, supporting the dual agonist approach for liver-directed metabolic therapy.Harrison SA et al., 2025 in J Hepatol. View on PubMed
- 2.The IMPACT Phase 2b trial, the largest controlled study of pemvidutide to date, evaluated weekly dosing in adults with biopsy-confirmed MASH. At 24 weeks, pemvidutide demonstrated significant improvements in histological endpoints, including MASH resolution and fibrosis improvement, alongside substantial liver fat reduction and body weight loss.Noureddin M et al., 2025 in Lancet. View on PubMed
- 3.Randomized controlled trial evaluating 24 weeks of pemvidutide treatment in adults with MASLD. The study demonstrated significant liver fat reduction by MRI-PDFF, improvements in ALT levels, and body weight loss, with a safety profile consistent with the GLP-1 receptor agonist class. The glucagon receptor component appeared to contribute additional hepatic benefits beyond weight loss alone.Browne SK et al., 2025 in JHEP Rep. View on PubMed
- 4.Review article discussing the rationale for dual GLP-1/glucagon receptor agonism. Glucagon receptor activation drives hepatic lipid oxidation and increases energy expenditure, while GLP-1 receptor activation reduces appetite and improves insulin sensitivity. This dual mechanism is particularly relevant to pemvidutide's observed effects on both liver fat and body weight.Sanchez-Garrido MA et al., 2017 in Diabetologia. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.